Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt

Abstract

Objectives

The aim of the study was to estimate the prevalence and associated correlates of major depressive disorder and generalized anxiety disorder in hepatitis C virus patients before and after treatment and to investigate the relationship between major depressive disorder and generalized anxiety disorder and treatment response.

Methods

A total of 116 consecutive hepatitis C virus patients from hepatitis C virus treatment center in Zagazig city, Egypt, were included in the study and divided into treated group (N = 58) and untreated group (N = 58). All hepatitis C virus patients were screened for major depressive disorder and generalized anxiety disorder using hospital anxiety and depression scale, and those who screened positive were interviewed to confirm the diagnosis of major depressive disorder and generalized anxiety disorder using DSM-IV-TR diagnostic criteria. These measures were done at baseline and after 12 weeks of treatment or observation.

Results

At baseline, 3.5% and 12.1% of hepatitis C virus patients (treated group) had major depressive disorder and generalized anxiety disorder, respectively. After 12 weeks of treatment 37.9% of hepatitis C virus patients (treated group) had major depressive disorder and 46.6% had generalized anxiety disorder. There was a significant statistical difference between hospital anxiety and depression scale scores for depression (3.3 ± 2.3 vs. 6.4 ± 3.2, t = 9.6, p = 0.001) and for anxiety (4.6 ± 2.4 vs. 7.3 ± 3.0, t = 10.2, p = 0.001) before and after treatment. There was also significant statistical difference between treated group and untreated group regarding hospital anxiety and depression scale scores after treatment and observation (depression, treated group 6.4 ± 3.2 vs. untreated group 4.0 ± 2.4, t = 3.7, p = 0.001; anxiety, treated group 7.3 ± 3.0 vs. untreated group 4.5 ± 2.3, t = 4.4, p = 0.001). There was no association between major depressive disorder and generalized anxiety disorder and treatment response.

Conclusions

Major depressive disorder and generalized anxiety disorder are common in hepatitis C virus patients after treatment with interferon and ribavirin and were not related to treatment response.

Keywords

Hepatitis C virus depression anxiety interferon ribavirin Egypt

Get full access to this article

View all access options for this article.

References

Schaefer

Capuron

Friebe

. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379–1390.

Mohamoud

Mumtaz

Abu-Raddad

. The epidemiology of hepatitis C virus in Egypt: a systematic review. Int J Infect Dis 2012; 16: 2–157.

Sarrazin

Berg

Ross

. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289–351.

El Sayed

Arafa

. Prospective study of psychiatric side effects during antiviral therapy of chronic hepatitis C in an Egyptian sample. Middle East Curr Psychiatry 2012; 19: 71–77.

Kraus

Schafer

Faller

. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708–714.

Bagheri

Fouladi

Barange

. Follow-up of adverse drug reactions from pegInterferon alpha2b-ribavirin therapy. Pharmacotherapy 2004; 24: 1546–1553.

Saunders

. Neuropsychiatric symptoms of hepatitis C. Issues Ment Health Nurs 2008; 29: 209–220.

Golden

O’Dwyer

Conroy

. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431–438.

Fishman

Murray

Eng

. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197: 597–607.

10.

Loftis

Huckans

Ruimy

. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1β and tumor necrosis factor-α. Neurosci Lett 2008; 430: 264–268.

11.

Quarantini

Bressan

Galvao

. Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007; 27: 1098–1102.

12.

Wobrock

Mihm

Löhr

. Cognition in hepatitis C patients treated with pegylated interferon. World J Biol Psychiatry 2009; 10: 819–826.

13.

Bonaccorso

Marino

Biondi

. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237–241.

14.

Horikawa

Yamazaki

Izumi

. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34–38.

15.

Morasco

Rifai

Loftis

. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83–90.

16.

Catherine

Gabriel

Wise

. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004; 71: 27–32.

17.

Sockalingam

Abbey

. Managing depression during hepatitis C treatment. Can J Psychiatry 2009; 54: 614–625.

18.

Dogar

Siddiqui

Bajwa

. Relationship between liver disease and levels of anxiety and depression. JPPS 2009; 6: 61–64.

19.

Zigmond

Snaith

. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.

20.

Hermann

. International experiences with the hospital anxiety and depression scale—a review of validation data and clinical results. J Psychosom Res 1997; 42: 17–41.

21.

Michopoulos

Douzenis

Kalkavoura

. Hospital anxiety and depression scale (HADS): validation in Greek general hospital sample. Ann Gen Psychiatry 2008; 7: 1–5.

22.

Martin

. What does the hospital anxiety and depression scale (HADS) really measures in liaison psychiatry settings? Curr Psychiatry Rev 2005; 1: 69–73.

23.

American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th ed, text-revision. Washington DC: American Psychiatric Association, 2000.

24.

SPSS for Windows. Statistical package for the social sciences. Version 11.0.1, Chicago, IL: SPSS Inc., 2001.

25.

Malyszczak

Inglot

Pawlowski

. Depressive symptoms during treatment with interferon alpha for HCV infection—preliminary report. Psychiatry Pol 2006; 40: 799–808.

26.

Navines

Castellvi

Moreno-Espana

. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the patient health questionnaire. J Affect Disord 2012; 138: 343–351.

27.

Ashrafi

Modabbernia

Dalir

. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. J Psychosom Res 2012; 73: 218–224.

28.

Miller

. Norman Cousins Lecture: mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009; 23: 149–158.

29.

Wichers

Koek

Robaeys

. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.

30.

Raison

Broadwell

Borisov

. Depressive symptoms and viral clearance in patients receiving interferon-a and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23–27.

31.

McHutchison

Gordon

Schiff

. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med 1998; 339: 1485.

32.

Hosoda

Takimura

Shibayama

. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54: 565–572.

33.

Shuto

Kataoka

Horikawa

. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348–351.

34.

Majer

Welberg

Capuron

. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008; 22: 870–880.

35.

Evon

Ramcharran

Belle

. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 2009; 104: 2949–2958.

36.

Raisson

Borisov

Broadwell

. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41–48.

37.

Smith

Norris

O’Farrelly

. Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr Dis Treat 2011; 7: 275–292.

38.

Udina

Castellvi

Moreno-Espana

. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128–1138.

39.

Pattullo

McAndrews

Damyanovich

. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int 2011; 31: 1028–1038.

40.

Wackernah

Lou

Park

. Retrospective chart review to assess the relationship between depression and sustained virological response from interferon treatment for hepatitis C virus. Clin Ther 2011; 33: 1400–1405.